Unlike CD19-specific chimeric antigen receptor (CAR) T-cell therapy which can cause serious neurological adverse events like seizure, cerebral edema, or encephalopathy, the administration of NY-ESO-1c259 T cells has not been linked with such toxicities [13]. The gene discussed is CD19; the disease is Encephalopathy.